450 filings
6-K
PPBT
Purple Biotech Ltd
14 Mar 24
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
7:40am
6-K
PPBT
Purple Biotech Ltd
6 Mar 24
Report of Foreign Private Issuer
4:06pm
20-F
2023 FY
PPBT
Purple Biotech Ltd
Annual report (foreign)
5 Mar 24
4:00pm
6-K
PPBT
Purple Biotech Ltd
5 Mar 24
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
7:58am
6-K
PPBT
Purple Biotech Ltd
27 Feb 24
Purple Biotech Presents Data of its Phase 1 Head & Neck Cancer of NT219 in combination with Cetuximab at ESMO TAT Congress 2024
7:10am
SC 13G
b0d a4xfcx9l6yonv5
14 Feb 24
PURPLE BIOTECH / ARMISTICE CAPITAL ownership change
3:49pm
6-K
0r0cggtrw6d 084bw
13 Feb 24
Purple Biotech Convenes a Head & Neck Cancer Scientific Advisory Board in Preparation for NT219 Phase 2 Trial
7:10am
6-K
cekv6ofkc70yx3lowndp
1 Feb 24
Report of Foreign Private Issuer
7:40am
6-K
9hk4d06mf0bl0g4h546c
26 Jan 24
Report of Foreign Private Issuer
4:15pm
6-K
s936fu4qcv42vbsd0h
20 Dec 23
Purple Biotech Appoints Dr. Yael Margolin to its Board of Directors
8:06am
6-K
jjps49ifspl2v
14 Dec 23
Purple Biotech Completes Patient Enrollment in Phase 2 Pancreatic Cancer Trial
7:00am
6-K
pjdkl
21 Nov 23
Report of Foreign Private Issuer
4:00pm
6-K
xatlje4ylpmp5sq8p
21 Nov 23
Purple Biotech Reports Third Quarter 2023 Financial Results
7:00am
EFFECT
foa0fc55pdii3
15 Nov 23
Notice of effectiveness
12:15am
424B3
bs5fwqu wmihvr6t
14 Nov 23
Prospectus supplement
4:13pm
F-1/A
kdcbjatb jq02
13 Nov 23
Registration statement (foreign) (amended)
4:11pm
CORRESP
8mxac202oy09snv5
13 Nov 23
Correspondence with SEC
12:00am
6-K
mrb2oskh3jjqtg
2 Nov 23
Purple Biotech Fortifies NT219 Patent Protection
7:04am
D
bg0bqo mgbj0
31 Oct 23
$5.43 mm in options / securities to be acquired, sold $5.43 mm, 1 investor
4:30pm
F-1
3pqvply
30 Oct 23
Registration statement (foreign)
4:30pm